Alzheimer’s disease (AD) is an irreversible neurodegenerative disease characterized by a progressive decline in cognition and memory, leading to significant impairment in daily activities and ultimately death. It is the most common cause of dementia, the prevalence of which increases with age; however, age is not the only predisposing factor. The pathology of this cognitive impairing disease is still not completely understood, which has limited the development of valid therapeutic options. Recent years have witnessed a wide range of novel approaches to combat this disease, so that they greatly increased our understanding of the disease and of the unique drug development issues associated with this disease. In this paper, we provide a brief overview of the history, the clinical presentation and diagnosis, and we undertake a comprehensive review of the various approaches that have been brought to clinical trials in recent years, including immunotherapeutic approaches, tau-targeted strategies, neurotransmitter-based therapies, neurotropic and hematopoietic growth factors, and antioxidant therapies, trying to highlight the lessons learned from these approaches.
Amirrad F, Bousoik E, Shamloo K, et al. Alzheimer’s disease: Dawn of a new era? J Pharm Pharm Sci. 2017; 20(0):184–225. doi: 10.18433/J3VS8P
Journal of Pharmacy and Pharmaceutical Sciences
Creative Commons License
This work is licensed under a Creative Commons Attribution-Share Alike 4.0 License.
Diagnosis Commons, Nervous System Diseases Commons, Neurology Commons, Neurosciences Commons, Other Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons, Therapeutics Commons
This article was originally published in Journal of Pharmacy and Pharmaceutical Sciences, volume 20, in 2017. DOI:10.18433/J3VS8P